Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone sublingual tablet for acute ischemic stroke
ChiCTR1900027408Phase 3Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of edaravone in ischemic stroke (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Proportion of patients with modified Rankin Scale score less than or equal to 1 at day 90. Started Nov 2019; status: recruiting.
02
Drugs
edaravone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR1900027408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027408.